



## PRESS RELEASE

### Oncodesign is granted new patent protecting key molecules generated from its Nanocyclix technology platform for next generation kinase inhibitors

- After the United States, Oncodesign's molecules are granted protection in Europe until 2032

**Dijon, May 30, 2016 – Oncodesign (ALONC - FR0011766229)**, a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment, is announcing today that it has received notification of the grant of patent EP2760453 by the European Patent Office. This patent protects novel macrocyclic compounds and their use as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2) that can be used in the treatment and diagnosis of diseases in which LRRK2 plays a major role, such as Parkinson's disease and Alzheimer's disease. The patent is valid until September 2032.

Filed jointly with Ipsen Pharma, Oncodesign's partner in Parkinson's disease, the same patent was granted in the United States in August 2015. Furthermore, it is currently under review in several other countries.

Oncodesign continues to add composition of matter and use protection to its intellectual property on molecules generated from its Nanocyclix medicinal chemistry technology. To date, Oncodesign has filed 11 patents that have either been approved or are under review protecting molecules and targets used in the Company's priority programs.

This latest notification complements the grants received in 2015 and 2016 covering a first patent related to kinase inhibitors developed based on the Nanocyclix technology, thus protecting a major part of this highly innovative platform in the United States and Europe.

Jan Hoflack, Chief Scientific Officer of Oncodesign, commented: *"The granting of a patent, a key milestone in protecting an innovation, completes the approval process by the relevant patent office and provides confirmation of the invention's novelty and ownership. With this new patent, Oncodesign is building an increasingly broad portfolio of enforceable patents to protect its innovative molecules and further establish its leadership in next-generation kinase inhibitor research."*

**Next financial publication:** Revenue for the first half of 2016, Monday July 18, 2016 (after the market close)

**About Oncodesign:** [www.oncodesign.com](http://www.oncodesign.com)

Founded over 20 years ago by Dr Philippe Genne, the Company's CEO and Chairman, Oncodesign is a biotechnology company that maximises the pharmaceutical industry's chances of success in discovering new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment. With its unique experience acquired by working with more than 500 clients, including the world's largest pharmaceutical companies, along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, advanced animal modelling and medical imaging, Oncodesign is able to predict and identify, at a very early stage, each molecule's therapeutic usefulness and potential to become an effective drug. Applied to kinase inhibitors, which represent a market estimated at over \$40 billion in 2016 and accounting for almost 25% of the pharmaceutical industry's R&D expenditure, Oncodesign's technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with pharmaceutical groups such as Bristol-Myers Squibb, Ipsen and UCB. Oncodesign is based in Dijon, France, in the heart of the town's university and hospital hub. It has 103 employees and subsidiaries in Canada and the USA.

## Contacts

### Oncodesign

Philippe Genne  
Chairman and CEO  
Tel: +33 (0)3 80 78 82 60  
[investisseurs@oncodesign.com](mailto:investisseurs@oncodesign.com)

### NewCap

Investor & Press Relations  
Julien Perez / Nicolas Merigeau  
Tel: +33 (0)1 44 71 98 52  
[oncodesign@newcap.eu](mailto:oncodesign@newcap.eu)

